NBT Bank N.A. Buys 19,292 Shares of GSK PLC Sponsored ADR $GSK

NBT Bank N.A. bought a new position in shares of GSK PLC Sponsored ADR (NYSE:GSK) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 19,292 shares of the pharmaceutical company’s stock, valued at approximately $929,000.

A number of other large investors have also modified their holdings of GSK. Root Financial Partners LLC purchased a new stake in GSK during the 3rd quarter valued at about $158,000. Cardinal Capital Management lifted its stake in GSK by 6.4% in the 3rd quarter. Cardinal Capital Management now owns 66,047 shares of the pharmaceutical company’s stock worth $3,211,000 after purchasing an additional 3,946 shares in the last quarter. Foster Victor Wealth Advisors LLC lifted its stake in GSK by 5.8% in the 3rd quarter. Foster Victor Wealth Advisors LLC now owns 438,220 shares of the pharmaceutical company’s stock worth $21,674,000 after purchasing an additional 23,934 shares in the last quarter. Axxcess Wealth Management LLC purchased a new position in GSK in the 3rd quarter worth approximately $382,000. Finally, Bell Bank boosted its holdings in shares of GSK by 1.6% during the 3rd quarter. Bell Bank now owns 184,064 shares of the pharmaceutical company’s stock worth $8,866,000 after purchasing an additional 2,830 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on GSK shares. Wolfe Research initiated coverage on GSK in a research report on Friday, October 9th. They issued an “outperform” rating and a $70.00 price target for the company. Berenberg Bank reiterated a “buy” rating on shares of GSK in a research report on Tuesday, October 6th. Barclays reissued a “sell” rating on shares of GSK in a research note on Monday, September 7th. Deutsche Bank Aktiengesellschaft restated a “neutral” rating on shares of GSK in a report on Tuesday, September 29th. Finally, Royal Bank Of Canada initiated coverage on GSK in a research note on Tuesday, September 8th. They issued a “sector perform” rating for the company. Four analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $55.33.

GSK Stock Performance

NYSE:GSK opened at $50.74 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52. The firm has a market capitalization of $102.64 billion, a price-to-earnings ratio of 15.87, a PEG ratio of 2.30 and a beta of 0.33. The company’s 50-day moving average is $49.59 and its two-hundred day moving average is $51.45. GSK PLC Sponsored ADR has a 1-year low of $42.85 and a 1-year high of $61.69.

GSK (NYSE:GSK) last announced its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.09. The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.47 EPS. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Analysts forecast that GSK PLC Sponsored ADR will post 4.78 EPS for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were paid a dividend of $0.4515 per share. This represents a $1.81 annualized dividend and a yield of 3.6%. This is a positive change from GSK’s previous quarterly dividend of $0.44. The ex-dividend date of this dividend was Friday, August 14th. GSK’s payout ratio is 55.31%.

GSK Company Profile

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.